

RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) REF NO : VSCD02ST Specimen type : Nasal Swab

#### STEP 1 PREPARATION



Familiarize yourself with the contents of the test kit in advance without opening the packaging of the components

Make sure to perform the test package contains the test cassette, a bottle with extraction buffer, a sterile swab, waste pochette and information for use.





() CAUTION: Samples should be used as soon as possible after collection.

# Place the buffer tube into holder

Place the bottle containing the extraction buffer solution into the tube holder and open it.



CAUTION: Be careful not to spill any of the liquid. M

CAUTION: Do not drink the extraction solution in  $(\mathbf{I})$ the tube. Immediately consult your healthcare professional if you drink it.



Sample collection

Carefully insert the sterile swab 2 cm into one nostril and rotate the swab 3 times close to the inner wall of the nose. Repeat the procedure with the same swab in the other



Rotate 10 times

Squeeze it

5 times

insert the swab with the swab sample into the bottle and dip the tip into the extraction buffer. Rotate the swab tip with the swab sample 10 times along the inner wall of the bottle. Squeeze the tip of the swab along the inner wall of the bottle to keep as much liquid in the bottle as possible.

①\*Make sure that the sample on the swab is detached as completely as possible into the buffer/test liquid. ①\*This process should take at least 20 seconds.



(!) CAUTION: Do not read after 20 minutes.

# **STEP 4** INTERPRETATION OF THE RESULTS

This product is for the qualitative detection of SARS-CoV-2 antigen only. Please consult your physician for medical advice before any kind of If both C- and T-line are appear, it indicates that SARS-CoV-2 antigen has been detected and the results is positive If the test result is positive: • Currently, there is a suspected infection of • Contact your doctor or local health department immediately · Comply with the local self-isolation guidelines Perform PCR test for confirmation Note: The intensity of the color in the test line region will vary depending on the concentration of COVID-19 antigen in the specimen. Therefore, any shade of color in the test region should be considered positive. If there is only a control line (C) appeared and the test line (T) is colorless, it indicates that SARSCoV-2 antigen has not been detected and the result is negative. If the test result is negative: Continue to comply with all applicable rules regarding contact and protective measures. • Even if the test is negative, there may be an In case of doubt, repeat the test after 1-2 days because the SARS-CoV-2 cannot be accurately detected at all stages of infection. If the control line (C) is not observed, the test is considered to be invalid whether the test line (T) is visible or not. A new test needs to be performed using a new test If the test result is invalid, it may be caused by incorrect test operation. Please repeat the test.If the test result is still invalid, please contact your doctor or COVID-19 testing **BIOHAZARD WASTE** DISPOSAL PROCEDURE Clean the area Sterilize or clean the area where the test is performed. To safely dispose of the test kit, place all the used material during the test (sample swab, extraction buffer tube, test cassette) in the biological waste pochette and seal it properly. Dispose the entire biological waste pochette immediately in the general waste bin. Wash hands with soap thoroughly or sanitize your hands after handling. Version: 21042022



#### RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) Reference Number: VSCD02ST For personal use only In-vitro diagnostic test for self-testing Instructions for use

## INTENDED USE

The RapidFor™ SARS-CoV-2 Rapid Antigen Test (Nasal) is a lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in human nasal swab specimens. The kit provides a rapid, on-the-spot result on the possible presence of COVID-19 infection in the individual person being tested. The test kit is designed for self-testing and does not require any special training for sample collection, processing, or test operation. The test can be performed by individuals older than ≥ 18 years old and users between 4-18 years old required guidance by adults. This kit is not suitable for children under 4 years old. The self-test is also used for monitoring of an existing disease, only adapt the treatment if he has received the appropriate training to do so.

Positive test result: A positive result provides evidence of SARS-CoV-2 infection. Please go into quarantine and contact a physician. A confirmatory test by using RT-PCR is necessary

Negative test result: A negative result does not exclude an infection with SARS-CoV-2 A negative test result is only a snapshot

Invalid Test Result: In the event of an invalid result, please repeat the test.

### SUMMARY AND EXPLANATION

The novel coronavirus SARS-CoV-2 is a positive-strand RNA virus and belongs to the β-genus of coronaviruses. COVID-19 is an acute respiratory infectious disease to which humans are susceptible. Currently, patients infected with SARS-CoV-2 are the main source of infection; asymptomatic infected persons can also transmit the virus. Based on current epidemiological investigation, the incubation period is 1 to 14 days, most commonly 3 to 7 days. The main manifestations include fever, fatigue, loss of smell and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea occur in a few cases.

### PRINCIPLE OF THE TEST

This reagent uses a double-antibody sandwich method for the qualitative detection of the Nucleocapsid antigen of SARS-CoV-2. During the test run, a colloidal gold-labelled anti-SARS-CoV-2 monoclonal antibody binds to the SARS-CoV-2 antigen in the sample. This reaction complex moves forward chromatographically on the nitrocellulose membrane, binding to the anti-SARS-CoV-2 monoclonal antibody pre-coated in the detection zone (T) on the test membrane, where it forms a red-stained reaction line. If the sample does not contain SARS-CoV- 2 antigen, no red color reaction line can be formed in the T zone.

At the same time, during the test run, a chicken IgY gold conjugate also moves along the membrane, binds to an anti-chicken IgY monoclonal antibody pre-coated in the quality control area C, and forms a red reaction line there. Regardless of whether the sample to be tested contains SARS-CoV-2 antigen, a red reaction line always forms in the quality control area (C).

# MATERIALS AND COMPONENTS

CATALOG NO	VSCD02ST01	VSCD02ST02	VSCD02ST05	
COMPONENT	(1 Test/Box)	(2 Tests/Box)	(5 Tests/Box)	
Test Device	1 Test cassette (1Test/pouch x 1 pouch)	2 Test cassettes (1Test/pouch x 2 pouches)	5 Test cassettes (1 Test/pouch x 5 pouches)	
Buffer	1 single-use bottle, each with 500 µL extraction buffer	2 single-use bottles, each with 500 μL extraction buffers	5 single-use bottles, each with 500 µL extraction buffers	
Specimen sampling swabs	1 sterile, single use specimen sampling swab	2 sterile, single use specimen sampling swabs	5 sterile, single use specimen sampling swabs	
Biological waste pochette	1 single-use, biological waste labeled pochette	1 single-use, biological waste labeled pochette	1 single-use, biological waste labeled pochette	
Packing Insert	1 instruction for use	1 instruction for use	1 instruction for use	

#### Materials required but not provided with the test kit - Timer

# Active components of the test cassette

Reagents

- mAb anti-COVID-19 antibody

- mAb anti-chicken IgY

- mAb anti-COVID-19 gold-conjugated antibody

- Purified chicken IgY gold conjugate

## STORAGE AND STABILITY

1.Store the test kit at 2°C - 30°C. Do not store or freeze the kit below 2°C. Do not store the test kit in direct sunlight. All components must be brought to room temperature before testing.

2.The test cassette must be used within 15 minutes after removal from the foil pouch.

3. The kit must not be used after the expiry date. The expiry date is stated on the label/packaging.

# LIMITATIONS

1. The result of the product must not be considered as a confirmed diagnosis. The evaluation of the test results must be done together with RT-PCR results, clinical symptoms, epidemiological information and further clinical data.

2. The contents of the kits are intended for the qualitative detection of SARS-CoV-2 in nasal samples. Neither the SARS-CoV-2 concentration nor the increase in concentration can be measured.

3. This test detects both viable (live) and non-viable antigens of viable SARS-CoV-2. 4. Test performance depends on the amount of virus (antigen) in the sample and may or may not correlate with the results of a virus culture performed on the same sample. 5.A negative test result may occur if the antigen concentration in a specimen is below the

detection limit of the test or if the specimen was improperly collected or transported. 6.Failure to follow the test procedure may adversely affect test performance and/or invalidate the test result. 7.A negative test result does not exclude the possibility of SARS-CoV-2 infection at any

time. Negative results can occur, for example, when the viral load is low, such as in the early incubation phase or from the second week after symptom onset and in asymptomatic individual. However, a false-negative test result can also occur if the sample was taken improperly, or the amount of virus is below the detection limit of the test. Please observe the hygiene rules and repeat the test if necessary.

8.If symptoms are ongoing after test results came negative, test again within 1-2 days to eliminate high risks and if your sample tests positive, please contact a health institution. A confirmatory test is necessary. To reduce the risk of transmission, rapid isolation after a positive test result is necessary. By contacting the doctor/health institution, entry into the reporting system then also takes place, in the case of a confirmed test result. 9.A positive test result does not exclude co-infections with other pathogens. 10.Negative test results do not exclude viral or bacterial infections other than SARS. 11.Negative results should be treated as presumptive and confirmed with a molecular assay. 12. If new SARS-COV-2 variants that may occur in the detection region may affect the detection limit of the test.

#### QUALITY CONTROL

A colored line in the control area (C) is considered an internal process control. It confirms complete penetration of the membrane with the sample, reactivity of the reagents, and correct test performance

# PERFORMANCE CHARACTERISTICS

1.Clinical Performance: The clinical performance of the RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) was

determined by comparison with an RT-PCR assay. Samples were taken within 7 days of symptom onset The performance of the RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) was

assessed using 663 nasal swabs. PCR-RT comparative test resul

CADE CoV 2 Donid				
Antigen Test Kit (Nasal)	Positive (+)	Negative (-)	Total	
Positive	198	3	201	
Negative	6	456	462	
Total	204	459	663	
Diagnostic Sensitivity: 198/204x 100 % = 97.06% , (95% CI: 93,71 - 98.91)				
Diagnostic Specificity: 456/459 × 100 % = 99.35%, (95% CI: 98.10 - 99.87)				
Accuracy: (198+456)/663 x 100 % = 98,64%, (95% CI: 97.44 - 99,38)				

\*Diagnostic Sensitivity: The ability of a device to identify the presence of a target marker associated with SARS-CoV-2

\*Diagnostic Specificity: The ability of a device to recognise the absence of a target market associated with SARS CoV-2 \*95% CI: Confidence intervals measure the degree of certainty in a sampling method, 95%

chance that the population mean lies within the interval 2. Analytical Performance

# a. Analytical Sensitivity

Limit of Detection (LOD)

At a viral culture concentration of 100 TCID<sub>so</sub>/mL and above, the positive level was greater than or equal to 95%. The minimum detection limit of the RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) is 100 TCID.,/mL. Variants

The test kit can detect the existing variants of SARS-CoV-2 (Alpha, Beta, Eta, Gamma, Delta, Omicron)

#### b. Analytical Specificity Cross Reactivity

The cross-reactivity of the kit was evaluated. The results showed no cross-reactivity with the following samples the following samples

No.	Specimen Type	Result
1	Human coronavirus-HKU1	106 TCID <sub>50</sub> /mL(In-silico)
2	Staphylococcus aureus	3x106 CFU /mL
3	Streptococcus pyogenes	1.6x106 CFU /mL
4	Measles virus	1.8x105 TCID <sub>50</sub> /mL
5	Paramyxovirus parotitis	1.0x105 TCID50/mL
6	Mycoplasma pneumoniae	1.3x 10 <sup>7</sup> CFU / mL
7	Human Metapneumovirus (hMPV)	2.4x105 TCID50/mL
8	Human coronavirus OC43	1.8x105 TCID50/mL
9	Human coronavirus NL63	1.8x105 TCID50/mL
10	Human coronavirus 229E	2.5x105 TCID <sub>50</sub> /mL
11	MERS Coronavirus	8.9x105 TCID <sub>50</sub> /mL
12	Bordetella parapertussia	1.0x105 CFU/mL
13	Influenza B (Victoria strain)	1.5x105 TCID 50/mL
14	Influenza B (Ystrain)	2.0x105 TCID <sub>50</sub> /mL
15	Influenza A (H1N1 2009)	1.8x105 TCID <sub>50</sub> /mL
16	Influenza A (H3N2)	2.0x105TCID <sub>50</sub> /mL
17	Avian influenza virus (H7N9)	1.0x105 TCID <sub>50</sub> /mL
18	Avian influenza virus (H5N1)	1.0x105 TCID <sub>50</sub> /mL
19	Epstein-Barr virus	1.0x10 <sup>7</sup> copies/mL
20	Enterovirus CA16	1.0x105 TCID <sub>50</sub> /mL
21	Human rhinovirus type 1	1.0x105 TCID <sub>50</sub> /mL
22	Human rhinovirus type 14	1.0x105 TCID <sub>50</sub> /mL
23	Respiratory syncytial virus A	1.2x105 TCID50/mL
24	Respiratory syncytial virus B	2.4x105 TCID <sub>50</sub> /mL
25	Streptococcus pneumoniae	1.8x10 <sup>6</sup> CFU / mL
26	Candida albicans	1.3x106 CFU / mL

27	Chlamydia pneumoniae	1.0x105 CFU/mL
28	Bordetella pertussis	5.8x10 <sup>6</sup> CFU /mL
29	Pneumocystis jirovecii	10 <sup>6</sup> CFU /mL (In-silico)
30	Mycobacterium tuberculosis	10º CFU / mL (In-silico)
31	Legionella pneumophila	2.0x106 CFU / mL
32	Human para-flu virus type 1	1.0x105 TCID50/mL
33	Human para-flu virus type 2	1.0x105 TCID50/mL
34	Human para-flu virus type 3	1.0x105 TCID <sub>50</sub> /mL
35	Human para-flu virus type 4	1.0x105 TCID50/mL
36	Haemophilus influenzae	2.7x106 CFU/mL
37	SARS-coronavirus	2.5x105 PFU/mL
38	Staphylococcus epidermidis	1.2x10 <sup>7</sup> CFU /mL
39	Mumps virus	3.2x105TCID50/mL
10	Enterovirus 70	3.1x10 <sup>5</sup> TCID <sub>50</sub> /mL
11	Human rhinovirus B70	1.0x105 TCID50/mL
12	Parainfluenza virus 1	1.8x105 TCID50/mL
13	Parainfluenza virus 2	4.3x105 TCID50/mL
14	Parainfluenza virus 3	1.6x105 TCID50/mL
15	Parainfluenza virus 4	1.3x105 TCID50/mL
16	Adenovirus Type 3	1.0x10 <sup>5</sup> TCID <sub>50</sub> /mL
17	Adenovirus Type 5	1.8x105 TCID50/mL
18	Adenovirus Type 7	1.8x105 TCID50/mL
19	Streptococcus salivarius	1.0x105 CFU/mL
50	Pseudomonas aeruginosa	1.0x105 CFU/mL

# Interference Substances

No.	Contaminants	Result	
1	Whole Blood	4%	
2	Ibuprofen	1mg / mL	
3	Tetracycline	3µg / mL	
4	Chloramphenicol	3µg / mL	
5	Erythromycin	3µg / mL	
6	Tobramycin Eye Drops	5%	
7	Throat spray (Menthol)	15%	
8	Mupirocine	10mg/mL	
9	Ice Throat candy (Menthol)	1.5mg/mL	
10	Tamiflu (Oseltamivir)	5mg/mL	
11	Naphthoxoline hydrochloride nasal drops	15%	
12	Mucin	0.50%	
13	Fisherman's Friend	1.5mg/mL	
14	Compound Benzocain Gel	1.5mg/mL	
15	Cromoglycate	15%	
16	Sinex (Phenylephrine Hydrochloride)	15%	
17	Afrin (Oxymetazoline)	15%	
18	Fluticasone propionate spray	15%	
19	Chloraseptic (Menthol/Benzocaine)	1.5 mg/mL	
20	Naso GEL (NeilMed)	5%	
21	CVS Nasal Spray (Cromolyn)	15%	
22	Zicam Cold Remedy	5%	
23	Homeopathic (Alkalol)	%10	
24	Sodium Cromolyn Eye Drops	15%	
25	Alkalol Nasal Wash	10%	
26	Throat Lozenge	1.5 mg/mL	
	6 mi ini ini	1	

# Precision

1.10 replicates of negative and positive samples were tested by using the reference materials of enterprises. The agreement between the negative and positive results was 100%.

2. Three different batches were tested with positive and negative reference materials. The agreement between the negative and positive results was 100%

#### Hook Effect

No hook effect was detected at a concentration of 5.0x106 TCID. /mL SARS-CoV-2. Usability Study

The usability study of the RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) was determined by comparison with an RT-PCR assay. Samples were taken within 7 days of symptom onset

The performance of the RapidFor™ SARS-CoV-2 Rapid Antigen Test Kit (Nasal) was assessed using 462 nasal swabs from patients.

RapidFor™	PCR-RT comparative test result		
SARS-CoV-2 Rapid Antigen Test Kit (Nasal)	Positive (+)	Negative (-)	Total
Positive	448	4	452
Negative	14	462	476
Total	462	466	928
Sensitivity: 448/462 x 100 % = 96.97%, (95% CI: 94.97 - 98.33)			
Specificity: 462/468 x 100 % = 99.14%, (95% CI: 97.82 - 99.77)			
Accuracy: (448+462)/928 x 100 % = 98.06%, (95% Cl: 96.95 - 98.85)			

# PRECAUTIONS

1.Do not use the kit contents beyond the expiration date printed on the outside of the box. 2.Do not reuse the used Test Card, Reagent Tube or Swab.

3. The aluminum pouch includes a test cassette and a silica gel. Silica gel is required to protect test cassette against environmental conditions. Do not use the test kit if the aluminum pouch does not include silica gel. Do not swallow the silica gel. When swallowed, immediately consult your healthcare profesional.

4.All users must read the instructions for use carefully before carrying out the test.

5.The sample buffer and test cassette must be brought to room temperature (18°C~30°C) before use, otherwise the results may be false. 6.Discard and do not use any damaged or dropped Test Card or material. 7. Users should test specimens as soon as possible after sample collection. 8. Do not spill any of the sample extraction solution. If you spill it, sterilize the area and if the amount of the sample extraction solution mixture is not enough to perform the test, repeat the test bey using new sampling swab and extraction solution tube. 9. Do not drink the extraction solution in the tube with or without swab. Immediately, consult your healthcare professional if you drink it. 10.If the sample volume is insufficient, the assay will not perform successfully.

11. The Reagent Solution contains a salt solution (saline). If the solution contacts the skin or eve, flush with copious amounts of water.

12.Inadequate or inappropriate storage and transport of all components and sample collection may vield false test results.

13. To obtain accurate results, do not use visually bloody or overly viscous specimens. 14. To obtain accurate results, an opened and exposed Test Card should not be used in

a heavily ventilated and moistured area.

15.Wash hands thoroughly after handling.

16.Do not touch the sample well or the membrane of the test cassette.

STMBOES USED		
COMPONENT	Material included	
11	This Side Up	
Ţ	Fragile	
IFU	Instruction for Use	
Ĩ.	Consult Instruction for Use	
() Warning	Warning	
2C SOC	Store at 2°C ~ 30°C (36 °F ~ 86 °F)	
EXP	Expiration Date	
	Manufacturer	
Ť	Keep Dry	
LOT	Lot Number	
BUFFER	Sample Buffer	
$\sim$	Date of Manufacture	
8	Do Not Reuse	
REF	Reference Number	
类	Keep Away From Sunlight	
$\overline{\mathbb{V}}_1$	Tests per Kit	
IVD	In Vitro Diagnostic Medical Device	
۲	Do not use if the package is damaged	
STERILE R	Sterilized with radiation	
STERILE EO	Sterilized with ethylene oxide	
(fi)	Keep away from children's reach	



Web: www.vitrosens.com Date of Issue: 21 04 2022